PT  - JOURNAL ARTICLE
AU  - Justin G. Peacock
AU  - Brendan O'Sullivan
AU  - Michael R. Povlow
TI  - A case of <sup>177</sup>Lu-DOTATATE (LUTATHERA) therapy without the use of antiemetics
AID  - 10.2967/jnmt.121.261996
DP  - 2021 Jul 01
TA  - Journal of Nuclear Medicine Technology
PG  - jnmt.121.261996
4099  - http://tech.snmjournals.org/content/early/2021/07/30/jnmt.121.261996.short
4100  - http://tech.snmjournals.org/content/early/2021/07/30/jnmt.121.261996.full
AB  - Recommended 177Lu-DOTATATE (LUTATHERA) treatment regimens involve prophylaxis with antiemetics to counteract the emetogenic properties of the nephroprotective amino acid solution infusion. We describe a 58-year-old female treated with LUTATHERA for metastatic small bowel carcinoid, who was allergic to many classes of antiemetics. Therefore, she was treated with LUTATHERA without antiemetic prophylaxis. She tolerated the compounded amino acid infusion of lysine/arginine, followed by LUTATHERA, without significant nausea or any vomiting. We hypothesize that aggressive antiemetic prophylaxis may not be necessary if a LUTATHERA patient receives compounded lysine/arginine amino acid solutions. The omission would decrease overall healthcare costs and limit possible medication side effects.